Drug intelligence / Profile preview

Immuzac

Development stage: Unknown
Lead developer: PuraPharm
Modality: Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

Immuzac is a botanical health product developed and marketed by PuraPharm. It is formulated as a standardized extract combining Yunzhi (*Coriolus versicolor*) and Lingzhi (*Ganoderma lucidum*), two fungi traditionally used in Chinese medicine for their purported health-promoting properties. The product is positioned as a functional health supplement designed to provide immune support and modulation. Unlike pharmaceutical drug candidates, Immuzac is not currently part of an active clinical development pipeline for specific therapeutic indications and is sold as a consumer nutraceutical product.

Brand names: Immuzac
Other names: Standardized Yunzhi Lingzhi Extract

Beyond the preview

Go deeper on Immuzac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immuzac.

Explore the full profile